A Phase I Study of Terameprocol in Patients with Recurrent Glioma

Print

Full Title

Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma (ABTC 1401)

Purpose

The purpose of this study is to find the highest dose of the investigational drug terameprocol that can be given safely in patients with high-grade glioma (including grade III anaplastic oligodendroglioma, grade III anaplastic astrocytoma, or grade IV glioblastoma) that has come back after prior treatment. Terameprocol interferes with the growth and reproduction of cancer cells by blocking proteins that these cells create to reproduce rapidly.

Terameprocol has been given intravenously (by vein) to people with high-grade glioma. Researchers think that giving the drug orally, in capsule form, will allow patients to take higher and more frequent doses, which may improve their tumor’s response to the treatment. Patients in this study will take the capsule form of the drug.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have high-grade glioma that has come back or continues to grow despite radiation therapy and chemotherapy.
  • Prior therapies, including bevacizumab, or current steroid treatment are allowed.
  • Patients shoulder recover from the serious side effects of prior treatments before entering the study.
  • Treatment with blood thinners is not permitted.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Anna Piotrowski at 212-610-0483.

Protocol

19-073

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators